Literature DB >> 1417115

HLA-B27 subtypes: implications for the spondyloarthropathies.

L MacLean1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1417115      PMCID： PMC1004796          DOI： 10.1136/ard.51.8.929

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  28 in total

1.  Specificity pockets for the side chains of peptide antigens in HLA-Aw68.

Authors:  T P Garrett; M A Saper; P J Bjorkman; J L Strominger; D C Wiley
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

2.  Infectious agents, immunity, and rheumatic diseases.

Authors:  B D Schwartz
Journal:  Arthritis Rheum       Date:  1990-04

3.  Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition.

Authors:  M H Breuning; C J Lucas; B S Breur; M Y Engelsma; G G de Lange; A J Dekker; W E Biddison; P Ivanyi
Journal:  Hum Immunol       Date:  1982-12       Impact factor: 2.850

4.  A factor(s) in Klebsiella culture filtrates specifically modifies an HLA-B27 associated cell-surface component.

Authors:  A F Geczy; K Alexander; H V Bashir; J Edmonds
Journal:  Nature       Date:  1980-02-21       Impact factor: 49.962

5.  Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders.

Authors:  R E Hammer; S D Maika; J A Richardson; J P Tang; J D Taurog
Journal:  Cell       Date:  1990-11-30       Impact factor: 41.582

6.  The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation.

Authors:  D R Madden; J C Gorga; J L Strominger; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

7.  Sulphydryl reactivity of the HLA-B27 epitope: accessibility of the free cysteine studied by flow cytometry.

Authors:  L MacLean; M Macey; M Lowdell; S Badakere; M Whelan; D Perrett; J Archer
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

8.  HLA-A and B polymorphisms predate the divergence of humans and chimpanzees.

Authors:  D A Lawlor; F E Ward; P D Ennis; A P Jackson; P Parham
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

9.  Genetic modulation of antigen presentation by HLA-B27 molecules.

Authors:  L Pazmany; S Rowland-Jones; S Huet; A Hill; J Sutton; R Murray; J Brooks; A McMichael
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

10.  Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease.

Authors:  P L Schwimmbeck; D T Yu; M B Oldstone
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307
View more
  6 in total

1.  HLA-B27 subtypes in the spondarthropathies.

Authors:  I L MacLean; S Iqball; P Woo; A C Keat; R A Hughes; G H Kingsley; S C Knight
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

2.  The peptide binding specificity of HLA-B27 subtypes.

Authors:  N Tanigaki; D Fruci; E Vigneti; G Starace; P Rovero; M Londei; R H Butler; R Tosi
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

Review 3.  The pathogenesis of HLA-B27 associated arthritis: lessons from the B27 crystal.

Authors:  H Kellner; D Yu
Journal:  Clin Investig       Date:  1994-03

4.  Seronegative spondyloarthropathies and HLA-B27 subtyes: a study in Asian Indians.

Authors:  U Kanga; N K Mehra; C L Larrea; N M Lardy; A Kumar; T E Feltkamp
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

5.  Comparison of the antibody responses to the 77 Klebsiella capsular types in ankylosing spondylitis and various rheumatic diseases.

Authors:  H Sahly; J Kekow; R Podschun; M Schaff; W L Gross; U Ullmann
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

6.  Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.

Authors:  J M Brooks; R J Murray; W A Thomas; M G Kurilla; A B Rickinson
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.